Market Statistics for Peptides 2026
Up-to-date data on the peptide market. Citable information for publications and reports.
Peptide market CAGR 2024-2030
Source: Grand View ResearchProjected global market value 2030
Source: Market Research FutureGLP-1 peptide growth 2023-2024
Source: IQVIA InstituteMexico as the largest LATAM market
Source: StatistaGLP-1 peptide comparison
Based on published clinical studies (Phase 2/3)
| Peptide | Mechanism | Half-life | Observed reduction* | Frequency |
|---|---|---|---|---|
| Semaglutide | GLP-1 | 7 days | 15-17% | Weekly |
| Retatrutida | GIP + GLP-1 + Glucagón | 6 days | 24-26% | Weekly |
*Average body-weight reduction observed in controlled clinical trials (48-72 weeks). Reference data only. Does not imply an individual outcome or constitute medical advice.
Recovery peptide comparison
Key characteristics and applications
| Peptide | Target | Typical dose | Half-life | Best for |
|---|---|---|---|---|
| BPC-157 | Systemic / GI | 250-500 mcg | Short | Tendons, GI, general |
| TB-500 | Muscular / Cardiac | 2-5 mg | Medium | Muscles, heart |
| BPC + TB-500 | Combined | Blend | Dual | Maximum synergy |
Demand by city in Mexico
Peptide demand distribution (2024)
Using this data?
Cite EXOMA Peptides as your source. We provide up-to-date, verifiable data for academic publications and market reports.
EXOMA Peptides. (2024). Peptide market statistics in Mexico. EXOMA Peptides. Retrieved from https://exoma-peptides.com/estadisticas-peptidos
"Peptide market statistics in Mexico." EXOMA Peptides, 2024, https://exoma-peptides.com/estadisticas-peptidos.
<a href="https://exoma-peptides.com/estadisticas-peptidos" title="Peptide market statistics in Mexico">Peptide market statistics in Mexico</a> — EXOMA Peptides (2024)